Research Papers:

Meta-analysis of the differentially expressed microRNA profiles in nasopharyngeal carcinoma

Junwen Luan, Junfu Wang, Qinghong Su, Xuemei Chen, Guosheng Jiang and Xiaoqun Xu _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:10513-10521. https://doi.org/10.18632/oncotarget.7013

Metrics: PDF 2325 views  |   HTML 2541 views  |   ?  


Junwen Luan1, Junfu Wang1, Qinghong Su1, Xuemei Chen2, Guosheng Jiang1, Xiaoqun Xu1

1Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, China

2Department of Otolaryngology, The Second Hospital of Shandong University, Jinan, Shandong 250033, China

Correspondence to:

Xiaoqun Xu, e-mail: [email protected]

Guosheng Jiang, e-mail: [email protected]

Keywords: nasopharyngeal carcinoma, miRNA, profiling, roubust rank aggregation method, meta-analysis

Received: July 02, 2015     Accepted: January 01, 2016     Published: January 25, 2016


MicroRNAs(miRNAs), as non-coding molecules, were proved to be correlated with gene expression in naspharyngeal carcinoma (NPC) development. In this research, a comprehensive meta-analysis of eight independent miRNA expression studies in NPC was preformed by using robust rank aggregation method (RRA), which contained a total of 775 tumor and 227 non-cancerous samples. There were 7 significant dysregulated miRNAs identified including three increased (miR-483–5p, miR-29c-3p and miR-205–5p) and four decreased (miR-29b-3p, let-7d-5p, miR-100– 5p and let-7g-5p) miRNAs. Subsequently, the miRNA target prediction and pathway enrichment analysis were carried out to find out the biological and functional relevant genes involved in the meta-signature miRNA regulation. Finally, several signaling and cancer pathogenesis pathways were suggested to be more frequently associated with the progression of NPC. In this research the meta-signature miRNA identified may be used to develop a series of diagnostic and prognostic biomarkers for NPC that serve specificity for use in clinics.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7013